OncoCyte, Corp. (Nasdaq: OCX), a precision diagnostics company, has recently released new data that demonstrates the effectiveness of VitaGraft Kidney in aiding physicians in treating kidney transplant patients with greater precision. The study focused on differentiating between two common causes of premature graft failure: antibody-mediated rejection (ABMR) and recurrent IgA nephropathy (IgAN). This groundbreaking research is the first to investigate the application of VitaGraft's diagnostic technology specifically for kidney transplant patients.
The study evaluated the performance of VitaGraft Kidney as a tool for distinguishing between recurrent IgAN and ABMR. The results showed that this test had higher sensitivity and specificity compared to routine tests like eGFR, uACR, and DSA. By accurately differentiating between these two conditions, physicians can make quicker treatment decisions and potentially avoid unnecessary procedures and treatments.
Professor Klemens Budde, MD, who leads the kidney transplantation department at Charité Universitätsmedizin Berlin, expressed his excitement about the outcome of this study.